In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SFDA To Disclose Government Information

This article was originally published in PharmAsia News

Executive Summary

China's State FDA will voluntarily disclose nine categories of government information including: organizational functions, personnel information, regulations and documents, announcements and notices, planning and programs, integration management, basic statistics, administrative permission and latest news. Citizens, legal entities and institutions may request such data from SFDA. Information such as quality bulletins, illegal drug advertisement notices, GMP and GSP authentication, adverse drug effects, tenders, key project approval and other details will be published at its website as well as via news conferences, newspapers, radio and TV to facilitate public access. The agency has officially started accepting such information requests since May 1. (Click here for more - Chinese Language)

You may also be interested in...



Allergan Declines To Confirm Abicipar Pegol Fate

There is speculation that it is the end of the road for abicipar pegol but Allergan has declined to say whether this is the case for the product that has been in development for wet AMD.

EU Industry Wants IVDR Delay, Grace Period For More Products And Phased Implementation

In the EU, voices calling for a postponement of the IVD Regulation’s 2022 enforcement date are growing louder.

Atox ‘Remains On Track’ Despite ACCUTE Setback

After talking with the FDA, Atox will file an NDA for its necrotizing soft tissue infections therapy despite missing primary endpoints in a pivotal trial, the biotech’s CEO tells Scrip.

UsernamePublicRestriction

Register

LL1132999

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel